Celgene falls on Revlimid setback
14:21 EDT 21 Jun 2012 | BioCentury
Celgene Corp. (NASDAQ:CELG) fell $7.72 (11%) to $59.45 on Thursday after withdrawing a European application to extend the label of multiple myeloma drug Revlimid lenalidomide. According to Celgene, EMA's CHMP needs more mature data before it can make..
Original Article: Celgene falls on Revlimid setback
More From BioPortfolio on "Celgene falls on Revlimid setback"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
